Analysts See $-0.13 EPS for Rexahn Pharmaceuticals, Inc. (RNN) as of May, 3

April 16, 2018 - By Jeanette Garcia

On May, 3 is awaited Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN)’s earnings report, according to Faxor. Last year’s EPS was $-0.2, while now analysts expect change of 35.00 % up from current $-0.13 EPS. Last quarter $-0.09 EPS was reported. Analysts forecasts 44.44 % negative EPS growth this quarter. RNN reached $1.615 on during the last trading session after $0.015 change.Currently Rexahn Pharmaceuticals, Inc. is downtrending after 70.78% change in last April 16, 2017. RNN has also 6,828 shares volume. The stock underperformed the S&P 500 by 82.33%.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer.The firm is worth $51.27 million. The company's clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer.Currently it has negative earnings. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma.

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: